Akkermansia muciniphila; YL44

Akkermansia muciniphila was isolated from wild type mouse. It is a Gram-negative, strictly anaerobic, non-motile, non-spore-forming, oval-shaped bacterium.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Product Information
Product Overview Akkermansia muciniphila was isolated from wild type mouse. It is a Gram-negative, strictly anaerobic, non-motile, non-spore-forming, oval-shaped bacterium.
Target Akkermansia
Genus Akkermansia
Strain Designation YL44
Application Study and research
Culture Medium Medium 693
Culture Conditions 37°C; Anaerobic
Source C57BL/6J wild type mouse
Risk Group 1
Genbank Accession Numbers 16S rRNA gene: KR364731
draft genome; raw reads: SRX1092354
Product Format Freeze-dried
Packaging Ampoule tube
Storage -80°C
Shelf Life 6 years
Target Introduction
Introduction Akkermansia is a genus in the phylum Verrucomicrobia; Bacteria with the type species Akkermansia muciniphila. Among the next-generation beneficial microbes that have been identified, Akkermansia muciniphila is a promising candidate. Akkermansia muciniphila is a strict anaerobe recently isolated from human faeces and uses the mucin as thesole sources of carbon and nitrogen elements. Due to this unique function and its high universality and richness in almost all life stages, Akkermansia muciniphila opened new avenues for the application in next-generation therapeutic probiotic. It is a bacterium of oval shape, non-motile and Gram-negative andforms no endospores and widely distributed in the intestines of human and animals. Akkermansia muciniphila is one of the normal gutsymbionts throughout our life. Currently, a large number of researches on Akkermansia muciniphila mainly focused on explaining its relationship with diseases. It promises to be a therapeutic target in the microbiota-related diseases, such as colitis, metabolic syndrome, immune diseases and cancer. Preliminary human datasuggest oral administration of Akkermansia muciniphila safe, butits effect needs to be further verified in more human clinical trials in the near future.
Alternative Names Akkermansia muciniphila; YL44
FAQs Published Data Customer Reviews Related Products
  1. How was Akkermansia muciniphila YL44 isolated?

    The strain YL44 was isolated from the feces of a C57BL/6J wildtype mouse. This origin highlights its relevance in research focused on the gut microbiome and its interactions with the host organism under various health and disease models.

  2. What are the potential research applications of Akkermansia muciniphila YL44?

    Research applications for Akkermansia muciniphila YL44 include studies on its role in gut barrier integrity, its immunomodulatory effects, and its potential to impact metabolic disorders like diabetes and obesity. Additionally, it may be used in studies examining the gut microbiome's response to dietary changes or pharmaceutical interventions.

  3. Is there any special protocol for reviving Akkermansia muciniphila YL44 from cryopreservation?

    To revive Akkermansia muciniphila YL44 from cryopreservation, it is recommended to gently thaw the frozen sample at room temperature and immediately inoculate it into pre-warmed culture media under strict anaerobic conditions to ensure recovery and minimize shock to the cells.

  4. What culture conditions are required for Akkermansia muciniphila YL44?

    Akkermansia muciniphila YL44 should be cultured at 37°C under anaerobic conditions. The bacterium is mesophilic, meaning it grows best at moderate temperatures without oxygen, making an anaerobic chamber or system necessary for cultivation.

  5. What unique genetic features does Akkermansia muciniphila YL44 possess?

    The strain YL44 has unique genomic characteristics, including specific prophages (phage regions within the genome) that may influence its behavior and interactions within the gut microbiome. These features make it a valuable model for studying bacterial adaptation and phage-host dynamics in the gut ecosystem.


Cooperation between an immunogenic and an acetate-producing species can suppress hyper-IgE

The research explores the effects of the bacterium Akkermansia muciniphila YL44 on immune regulation, particularly focusing on how microbial colonization influences serum IgE levels, a marker commonly associated with allergies and immune responses. The research utilized gnotobiotic mouse models to elucidate the roles of specific microbes and their metabolites in modulating immune responses. The experiments demonstrated that early-life colonization with Akkermansia muciniphila YL44, among other bacterial species, could significantly influence the production of IgE, potentially offering a pathway to mitigate hygiene-related increases in IgE typically seen in overly sterile environments.
A pivotal finding from the study was the identification of specific bacterial characteristics crucial for suppressing IgE levels. These included the ability of the bacteria to produce acetate and their immunogenicity, particularly the ability to induce IgA production in the host. These microbial actions appeared essential for moderating immune responses conducive to reducing allergy risks. The study's implications suggest that manipulating gut microbiota composition, especially during the early stages of development, could be a viable strategy to prevent or reduce allergies, underscoring the significant impact of microbial residents in immune system maturation and function.

Wyss, M., Brown, K., et al. Using precisely defined in vivo microbiotas to understand microbial regulation of IgE. Frontiers in immunology. 2020, 10: 479611.

  • Pioneering Research Tool
    Creative Biolabs' Akkermansia muciniphila YL44 has proven exceptional in comparative microbiome studies. It offers reliable reproducibility and enhanced viability, outperforming competitors in precision and application.
  • Viability and Consistency
    Using Akkermansia muciniphila YL44 from Creative Biolabs has significantly elevated our research outcomes. Its superior viability and consistency enable groundbreaking discoveries in metabolic syndrome research.
  • Quality and Effectiveness
    Creative Biolabs has delivered an unparalleled product with their Akkermansia muciniphila YL44. Its effectiveness in our pathogen interaction studies is unmatched, offering distinct advantages over other market options.
  • Leader in Microbial Research Applications
    Creative Biolabs' Akkermansia muciniphila YL44 remains the leader in microbial research applications. Its adaptability and robust results are essential for studying complex microbial ecosystems.
  • A Critical Resource for Pathogenesis Research
    Relying on Akkermansia muciniphila YL44 has accelerated our research into microbial pathogenesis. Its high-quality, stable cultures provide critical insights faster than ever before.

Click the button below to contact us or submit your feedback about this product.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutic

Contact us

Copyright © 2024 Creative Biolabs. All Rights Reserved.

Inquiry Basket